Ignite Creation Date:
2024-05-05 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00490490
Status:
TERMINATED
Last Update Posted:
2017-03-29
First Post:
2007-06-20
Brief Title:
Study of Bexxar Tositumomab Combined With External Beam Radiation Therapy
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
Study of Bexxar Tositumomab Combined With External Beam Radiation Therapy for Patients With Relapsed Bulky Non-Hodgkins Lymphoma
Status:
TERMINATED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Low Accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to assess the response rate of patients with relapsed or refractory low-grade or transformed low-grade CD20-positive B-cell non-Hodgkins lymphoma to Iodine-131 I-131 tositumomab Bexxar therapy plus local palliative radiation therapy XRT
Detailed Description:
Response will be assessed on the basis of the presence or absence of measurable lesion 14 x 14 cm operationally defined as 20 cm2 by radiographic evaluation OR 10 cm in greatest diameter detected by palpation on physical exam
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| LYMNHL0046 | OTHER | OnCore | None |
| 97437 | OTHER | None | None |